STOCK TITAN

DermTech to Announce Fourth Quarter and Full-Year Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

DermTech, Inc. (NASDAQ: DMTK) will release its fourth quarter and full-year 2021 financial results on March 1, 2022, after market close. A conference call to discuss these results will follow at 1:30 p.m. PT / 4:30 p.m. ET. Interested participants can access the call by dialing (844) 467-7114 for domestic or (409) 231-2086 for international calls, using conference ID 8994008. DermTech is focused on precision dermatology through a non-invasive skin genomics platform aimed at improving early detection of skin cancers and customizing treatments.

Positive
  • Focus on precision dermatology with innovative non-invasive genomic analysis.
  • Upcoming earnings release and conference call may provide new insights for investors.
Negative
  • None.

LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it plans to release its fourth quarter and full-year 2021 financial results after the market closes on Tuesday, March 1, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (844) 467-7114 for domestic callers or (409) 231-2086 for international callers, using conference ID: 8994008. The live webinar for the call may be accessed by visiting the Events section of the Company's website at investors.DermTech.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

About DermTech:

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech's mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech's investor relations site at: www.dermtech.com.

DermTech

Sarah Dion

sdion@dermtech.com

858.450.4222

ICR Westwicke IR

Caroline Corner, PhD

caroline.corner@westwicke.com

415.202.5678

Source: DermTech, Inc.

FAQ

When will DermTech release its financial results for 2021?

DermTech, Inc. will release its fourth quarter and full-year 2021 financial results on March 1, 2022.

What time is the DermTech conference call scheduled for?

The conference call to discuss DermTech's financial results is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on March 1, 2022.

How can I access the DermTech conference call?

Participants can access the call by calling (844) 467-7114 for domestic or (409) 231-2086 for international attendees, using conference ID 8994008.

What is DermTech's focus area in dermatology?

DermTech is focused on precision dermatology through its non-invasive skin genomics platform, aimed at early detection of skin cancers.

DermTech, Inc.

NASDAQ:DMTK

DMTK Rankings

DMTK Latest News

DMTK Stock Data

3.29M
34.96M
2.62%
18.09%
8.64%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SAN DIEGO